155 related articles for article (PubMed ID: 27561316)
1. How I treat essential thrombocythemia.
Rumi E; Cazzola M
Blood; 2016 Nov; 128(20):2403-2414. PubMed ID: 27561316
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
3. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
5. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
6. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
8. Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort.
Randi ML; Geranio G; Bertozzi I; Micalizzi C; Ramenghi U; Tucci F; Notarangelo LD; Ladogana S; Menna G; Giordano P; Consarino C; Farruggia P; Zanazzo GA; Fiori GM; Burnelli R; Russo G; Jankovich M; Peroni E; Duner E; Basso G; Fabris F; Putti MC
Br J Haematol; 2015 May; 169(4):584-9. PubMed ID: 25716342
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia.
Martínez-Avilés L; Álvarez-Larrán A; Besses C; Navarro G; Torres E; Longarón R; Angona A; Pedro C; Florensa L; Serrano S; Bellosillo B
Ann Hematol; 2012 Oct; 91(10):1555-62. PubMed ID: 22706669
[TBL] [Abstract][Full Text] [Related]
10. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
[TBL] [Abstract][Full Text] [Related]
11. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
13. Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P; Vannucchi AM
Blood Rev; 2020 Jul; 42():100714. PubMed ID: 32546373
[TBL] [Abstract][Full Text] [Related]
14. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
15. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
Rotunno G; Mannarelli C; Guglielmelli P; Pacilli A; Pancrazzi A; Pieri L; Fanelli T; Bosi A; Vannucchi AM;
Blood; 2014 Mar; 123(10):1552-5. PubMed ID: 24371211
[TBL] [Abstract][Full Text] [Related]
16. JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report.
Yhim HY; Kim HS; Sohn JY; Song MJ; Lee NR; Song EK; Choi SI; Yim CY; Kwak JY
Cancer Genet Cytogenet; 2010 Apr; 198(2):162-5. PubMed ID: 20362232
[TBL] [Abstract][Full Text] [Related]
17. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
18. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
19. New advances in the pathogenesis and therapy of essential thrombocythemia.
Levine RL; Heaney M
Hematology Am Soc Hematol Educ Program; 2008; ():76-82. PubMed ID: 19074062
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
Milosevic Feenstra JD; Nivarthi H; Gisslinger H; Leroy E; Rumi E; Chachoua I; Bagienski K; Kubesova B; Pietra D; Gisslinger B; Milanesi C; Jäger R; Chen D; Berg T; Schalling M; Schuster M; Bock C; Constantinescu SN; Cazzola M; Kralovics R
Blood; 2016 Jan; 127(3):325-32. PubMed ID: 26423830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
